The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global electrophysiology devices market reached a value of US$ 6.1 Billion in 2020. Electrophysiology (EP) devices refer to various medical equipment that are used for the diagnosis and treatment of cardiological ailments. These devices analyze the electrical impulses of the heart and evaluate abnormal heartbeats. Some of the commonly used EP devices include implantable cardioverter defibrillators (ICDs), pacemakers, automated external defibrillators (AEDs), cryoablation EP catheters, radiofrequency ablation catheters and microwave and laser ablation systems. These devices send and receive electrical signals to and from the heart to regulate the heartbeat in case of an emergency. They are minimally invasive and also aid in removing dysfunctional heart tissues that can cause irregular heart rhythms.
The increasing prevalence of arrhythmia and other cardiovascular diseases (CVDs) across the globe is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such medical ailments, is also providing a boost to the market growth. The increasing awareness regarding the benefits of EP devices that have minimal risks and higher success rates as compared to the traditionally used devices has created a positive outlook for the market. Additionally, the advent of innovative technologies, such as cryo-, laser and ultrasound ablation and advanced mapping systems, are also contributing to the market growth. Product manufacturers are developing variants that are compact and portable and are also suitable for patients suffering from hypertension, diabetes and other medical ailments. Other factors, including the increasing requirement of EP devices for continuous monitoring, diagnosis and treatment of CVDs in both residential and hospital settings, along with significant improvements in the healthcare infrastructure, are expected to drive the market further. Looking forward, IMARC Group expects the global electrophysiology devices market to grow at a CAGR of 9.2% during 2021-2026.
IMARC Group provides an analysis of the key trends in each sub-segment of the global electrophysiology devices market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product, indication and end user.
Breakup by Product:
Breakup by Indication:
Breakup by End User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Biosense Webster Inc. (Johnson & Johnson), Biotronik SE & Co. KG, Boston Scientific Corporation, Cardiofocus Inc., Koninklijke Philips N.V., Medtronic Inc., MicroPort Scientific Corporation, Molecular Devices LLC ( Danaher Corporation), Nihon Kohden Corporation, Siemens Healthcare GmbH and Stereotaxis Inc.
The global electrophysiology devices market was valued at US$ 6.1 Billion in 2020.
We expect the global electrophysiology devices market to exhibit a CAGR of 9.2% during 2021-2026.
The rising geriatric population, along with the increasing awareness regarding numerous benefits of EP devices with minimal risks and higher success rates, represent some of the key factors driving the global electrophysiology devices market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of numerous elective treatment procedures for cardiological ailments to reduce the risk of coronavirus infection upon hospital visits, thereby limiting the demand for electrophysiology devices.
Based on the product, the global electrophysiology devices market can be segmented into treatment devices and diagnostic devices. Currently, diagnostic devices hold the majority of the global market share.
Based on the indication, the global electrophysiology devices market has been divided into Atrial Fibrillation (AF), Supraventricular Tachycardia, Atrioventricular Nodal Re-entry Tachycardia (AVNRT), Wolff-Parkinson-White syndrome (WPW), Bradycardia, and others, where Atrial Fibrillation (AF) currently exhibits a clear dominance in the market.
Based on the end user, the global electrophysiology devices market can be categorized into hospitals, diagnostic centers, and others. Among these, hospitals currently account for the largest market share.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global electrophysiology devices market include Biosense Webster Inc. (Johnson & Johnson), Biotronik SE & Co. KG, Boston Scientific Corporation, Cardiofocus Inc., Koninklijke Philips N.V., Medtronic Inc., MicroPort Scientific Corporation, Molecular Devices LLC (Danaher Corporation), Nihon Kohden Corporation, Siemens Healthcare GmbH, and Stereotaxis Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at